Chitosan-modified manganese oxide-conjugated methotrexate nanoparticles delivering 5-aminolevulinic acid as a dual-modal T1-T2* MRI contrast agent in U87MG cell detection.

Autor: Ayyami Y; Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Ghorbani M; Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Iran Polymer and Petrochemical Institute, P.O.Box: 14965/115, Tehran, Iran., Dastgir M; Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Malekzadeh R; Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. reza.malek78@yahoo.com., Mortezazadeh T; Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. tmortezazadeh@gmail.com.; Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. tmortezazadeh@gmail.com.
Jazyk: angličtina
Zdroj: Magma (New York, N.Y.) [MAGMA] 2024 Oct; Vol. 37 (5), pp. 909-924. Date of Electronic Publication: 2024 May 25.
DOI: 10.1007/s10334-024-01169-4
Abstrakt: Objective: Glioblastoma multiforme is a highly aggressive form of brain cancer, and early diagnosis plays a pivotal role in improving patient survival rates. In this regard, molecular magnetic resonance imaging has emerged as a promising imaging modality due to its exceptional sensitivity to minute tissue changes and the ability to penetrate deep into the brain. This study aimed to assess the efficacy of a novel contrast agent in detecting gliomas during MRI scans.
Materials and Methods: The contrast agent utilized modified chitosan coating on manganese oxide nanoparticles. The modification included adding methotrexate and 5-aminolevulinic acid (MnO 2 /CS@5-ALA-MTX) to target cells with overexpressed folate receptors and breaking down excess hydrogen peroxide in tumor tissue, resulting in enhanced signal intensity in T 1 -weighted MR images but diminished signal intensity in T 2 *-weighted MR images.
Results: The nanosystem was characterized and evaluated in MR imaging, safety, and ability to target cells both in vivo and in vitro. MTX-free nanoparticles (MnO 2 /CS@5-ALA NPs) had no obvious cytotoxicity on cell lines U87MG and NIH3T3 after 24/48 h at a concentration of up to 160 µgr/mL (cell viability more than 80%). In this system, methotrexate enables tumor targeting and the MnO 2 /5-ALA improves T 1 -T 2 * -weighted MRI. In addition, MRI scans of mice with M109 carcinoma indicated significant tumor uptake and NP capacity to improve the positive contrast effect.
Conclusion: This developed MnO 2 /CS@5-ALA-MTX nanoparticle system may exhibit great potential in the accurate diagnosis of folate receptor over-expressing cancers such as glioblastoma.
(© 2024. The Author(s), under exclusive licence to European Society for Magnetic Resonance in Medicine and Biology (ESMRMB).)
Databáze: MEDLINE
Externí odkaz: